2023 World Conference on Lung Cancer (Posters)-EP13.03. Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study

EP13.03. Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the efficacy and safety of anlotinib monotherapy as maintenance therapy following induction chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC). The study enrolled 27 ES-SCLC patients who were in stable condition after first-line chemotherapy. These patients received oral anlotinib (12 mg/d) for 14 days every 21 days as a course, until disease progression or unmanageable toxicity occurred. The primary endpoint of the study was median progression-free survival (mPFS), while secondary endpoints included median duration of response (mDOR), median overall survival (mOS), and safety.<br /><br />The results showed that the mPFS was 252 days, with a 95% confidence interval (CI) of 217.782-286.218. The mDOR was 126 days, with a 95% CI of 98.899-153.101. The mOS was not reached, as only 7 patients reached this endpoint while 20 patients survived. The most common treatment-related adverse events were hypertension, fatigue, and poor appetite. Despite these adverse reactions, patients were generally able to tolerate the treatment with anlotinib and had a favorable prognosis. Importantly, no patients required a dose reduction due to the severity of adverse events.<br /><br />In conclusion, anlotinib showed prospective efficacy and manageable safety as a maintenance treatment for ES-SCLC. The findings highlight anlotinib as a tolerable and potent option for maintenance therapy in this patient population, providing additional evidence-based support for clinical treatment regimens.

Asset Subtitle

Fanming Kong

Meta Tag

Speaker Fanming Kong

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

anlotinib monotherapy

maintenance therapy

induction chemotherapy

extensive-stage small-cell lung cancer

ES-SCLC

efficacy

safety

progression-free survival

duration of response

overall survival